Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.

(2017) B. Y. Karlan et al.   JOURNAL OF CLINICAL ONCOLOGY

Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth

(2010) H. Hashizume et al.   CANCER RESEARCH

Angiopoietin-2 Promotes Disease Progression of Neuroendocrine Tumors

(2010) K. M. Detjen et al.   CLINICAL CANCER RESEARCH

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

(2010) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

(2010) J. L. Brown et al.   MOLECULAR CANCER THERAPEUTICS

Preoperative Serum Angiopoietin-2 Levels Correlate with Lymph Node Status in Patients with Early Gastric Cancer

(2009) Min Jung Jo et al.   ANNALS OF SURGICAL ONCOLOGY

Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma

(2009) I. Helfrich et al.   CLINICAL CANCER RESEARCH

Reversibility of Epithelial-Mesenchymal Transition (EMT) Induced in Breast Cancer Cells by Activation of Urokinase Receptor-dependent Cell Signaling

(2009) Minji Jo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis

(2009) Marta Koch et al.   JOURNAL OF PATHOLOGY

Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium

(2009) H. T. Yuan et al.   MOLECULAR AND CELLULAR BIOLOGY

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

(2009) Hellmut G. Augustin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Angiopoietin-1 induces neurite outgrowth of PC12 cells in a Tie2-independent, β1-integrin-dependent manner

(2009) Xinyu Chen et al.   NEUROSCIENCE RESEARCH

Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies

(2008) P. Kumpers et al.   BLOOD

Reduced Glioma Growth Following Dexamethasone or Anti-Angiopoietin 2 Treatment

(2008) Jérôme Villeneuve et al.   BRAIN PATHOLOGY

Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis

(2008) P Schulz et al.   BRITISH JOURNAL OF CANCER

Preoperative CA19-9 Levels and Lymph Node Ratio Are Independent Predictors of Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma

(2008) R.A. Smith et al.   DIGESTIVE SURGERY

The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1

(2008) Marie-Pierre Simon et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2

(2008) Yvonne Reiss et al.   JOURNAL OF PATHOLOGY

Inhibition of In Vivo Tumor Angiogenesis and Growth Via Systemic Delivery of an Angiopoietin 2-Specific RNA Aptamer

(2008) Shiva Sarraf-Yazdi et al.   JOURNAL OF SURGICAL RESEARCH